A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
Start Date
10/24/2024
Completion Date
12/31/2028
Summary
A study to learn about the treatment LTP001 in healthy participants (Part A) and in participants with PAH (Part B)
Detailed Description
The CLTP001A12202 study will explore the safety, tolerability, and pharmacokinetics of LTP001 in healthy volunteers (Part A) and will evaluate the safety and efficacy (Part B) followed by safety extension in participants with pulmonary arterial hypertension.
Eligibility Criteria
Age Range: 18 years to 100 years
Interventions
LTP
Placebo
Conditions
Locations
Arizona Pulmonary Specialists Ltd
Scottsdale, Arizona 85258
United States
UC Irvine Medical Center
Orange, California 92868-3298
United States
Stanford Medical Center
Stanford, California 94305
United States
Univ Colorado Hospital
Aurora, Colorado 80045
United States
Central Florida Pulmonary Group
Orlando, Florida 32803-5734
United States
University of South Florida
Tampa, Florida 33606-3475
United States
Emory University School of Medicine
Atlanta, Georgia 30322
United States
U of Kansas Medical Center
Kansas City, Kansas 66160
United States
Norton Infectious Diseases Specialists
Louisville, Kentucky 40202
United States
Tufts Medical Center
Boston, Massachusetts 02111
United States
Lahey Hospital and Medical Center
Burlington, Massachusetts 01805
United States
Sky Integrative Medical Center SKYCRNG PPDS
Ridgeland, Mississippi 39157-5179
United States
Summit Health Eastside Clinic
Bend, Oregon 97701
United States
Allegheny General Hospital
Pittsburgh, Pennsylvania 15212-4756
United States
Statcare Pulmonary Consultants
Knoxville, Tennessee 37919
United States
PPD Development LP
Austin, Texas 78744
United States
PPD Development LP
Austin, Texas 78744
United States
UT Southwestern Medical Center
Dallas, Texas 75390
United States
The University of Utah
Salt Lake City, Utah 84132-0001
United States
Pul Ass Richmond Inc P A R
Richmond, Virginia 23230-1709
United States
Novartis Investigative Site
Buenos Aires, Buenos Aires F.D. 1199
Argentina
Novartis Investigative Site
CABA, C1426ABP
Argentina
Novartis Investigative Site
Río Cuarto, X5800AEV
Argentina
Novartis Investigative Site
San Miguel de Tucumán, T4000AXL
Argentina
Novartis Investigative Site
Santa Fe, S3000EOZ
Argentina
Novartis Investigative Site
Camperdown, New South Wales 2050
Australia
Novartis Investigative Site
Darlinghurst, New South Wales 2010
Australia
Novartis Investigative Site
New Lambton Heights, New South Wales 2305
Australia
Novartis Investigative Site
Adelaide, South Australia 5000
Australia
Novartis Investigative Site
Leuven, Vlaams Brabant 3000
Belgium
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul 90035-074
Brazil
Novartis Investigative Site
Prague, 128 08
Czechia
Novartis Investigative Site
Prague, 14021
Czechia
Novartis Investigative Site
Angers, France 49933
France
Novartis Investigative Site
Brest, 29200
France
Novartis Investigative Site
Clamart, 92141
France
Novartis Investigative Site
Grenoble, 38043
France
Novartis Investigative Site
Montpellier, 34295
France
Novartis Investigative Site
Nice, 06001
France
Novartis Investigative Site
Pessac, 33604
France
Novartis Investigative Site
Poitiers, 86021
France
Novartis Investigative Site
Saint-Priest-en-Jarez, 42270
France
Novartis Investigative Site
Strasbourg, 67091
France
Novartis Investigative Site
Toulouse, 31059
France
Novartis Investigative Site
Vandœuvre-lès-Nancy, 54511
France
Novartis Investigative Site
Regensburg, Bavaria 93053
Germany
Novartis Investigative Site
Dresden, Saxony 01307
Germany
Novartis Investigative Site
Berlin, 13125
Germany
Novartis Investigative Site
Berlin, 14050
Germany
Novartis Investigative Site
Giessen, 35392
Germany
Novartis Investigative Site
Greifswald, 17475
Germany
Novartis Investigative Site
Heidelberg, 69120
Germany
Novartis Investigative Site
Homburg, 66421
Germany
Novartis Investigative Site
Athens, 106 76
Greece
Novartis Investigative Site
Chaïdári, 124 62
Greece
Novartis Investigative Site
Thessaloniki, 54636
Greece
Novartis Investigative Site
Foggia, FG 71122
Italy
Novartis Investigative Site
Monza, MB 20900
Italy
Novartis Investigative Site
Palermo, PA 90127
Italy
Novartis Investigative Site
Pavia, PV 27100
Italy
Novartis Investigative Site
Roma, RM 00161
Italy
Novartis Investigative Site
Sassari, SS 07100
Italy
Novartis Investigative Site
Ivrea, TO 10015
Italy
Novartis Investigative Site
Trieste, TS 34149
Italy
Novartis Investigative Site
Riga, LV 1002
Latvia
Novartis Investigative Site
Monterrey, Nuevo León 64460
Mexico
Novartis Investigative Site
Monterrey, Nuevo León 64718
Mexico
Novartis Investigative Site
San Luis Potosí City, San Luis Potosí 78200
Mexico
Novartis Investigative Site
Poznan, 61 545
Poland
Novartis Investigative Site
Almada, 2805-267
Portugal
Novartis Investigative Site
Lisbon, 1769 001
Portugal
Novartis Investigative Site
Timișoara, Timiș County 300310
Romania
Novartis Investigative Site
Bucharest, 050159
Romania
Novartis Investigative Site
Belgrade, Serbia 11000
Serbia
Novartis Investigative Site
Kamenitz, 21204
Serbia
Novartis Investigative Site
Niš, 18108
Serbia
Novartis Investigative Site
Santiago Compostela, A Coruna 15706
Spain
Novartis Investigative Site
Marbella, Andalusia 29600
Spain
Novartis Investigative Site
Toledo, Castille-La Mancha 45071
Spain
Novartis Investigative Site
Barcelona, Catalonia 08003
Spain
Novartis Investigative Site
Las Palmas de Gran C, Las Palmas 35016
Spain
Novartis Investigative Site
Barcelona, 08035
Spain
Novartis Investigative Site
Seville, 41013
Spain
Novartis Investigative Site
Sheffield, South Yorkshire S10 2JF
United Kingdom
Novartis Investigative Site
Cambridge, CB2 0AY
United Kingdom
Novartis Investigative Site
London, EC1A 7BE
United Kingdom
Novartis Investigative Site
London, SW3 6PH
United Kingdom